Beyond COVID-19: the promise of next-generation coronavirus vaccines DOI Creative Commons

Reshma Koolaparambil Mukesh,

Claude Kwe Yinda, Vincent J. Munster

и другие.

npj Viruses, Год журнала: 2024, Номер 2(1)

Опубликована: Авг. 22, 2024

Abstract Coronaviruses (CoVs) have caused three global outbreaks: severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in 2003, Middle East (MERS-CoV) 2012, and SARS-CoV-2 2019, with significant mortality morbidity. The impact of disease 2019 (COVID-19) raised serious concerns about the preparedness for a pandemic. Furthermore, changing antigenic landscape led to new variants increased transmissibility immune evasion. Thus, development broad-spectrum vaccines against current future emerging CoVs will be an essential tool pandemic preparedness. Distinct phylogenetic features within complicate limit process generating pan-CoV vaccine capable targeting entire Coronaviridae family. In this review, we aim provide detailed overview CoVs, their phylogeny, various efforts developing vaccines, future.

Язык: Английский

Update on the omicron sub‐variants BA.4 and BA.5 DOI
Trina Ekawati Tallei, Saad Alhumaid, Zainab AlMusa

и другие.

Reviews in Medical Virology, Год журнала: 2022, Номер 33(1)

Опубликована: Авг. 26, 2022

Abstract Several nations have recently begun to relax their public health protocols, particularly regarding the use of face masks when engaging in outdoor activities. This is because there has been a general trend towards fewer cases coronavirus disease 2019 (COVID‐19). However, new Omicron sub‐variants (designated BA.4 and BA.5) emerged. These two subvariants are thought be cause an increase COVID‐19 South Africa, United States, Europe. They also spread throughout Asia. evolved from lineage with characteristics that make them even more contagious which allow circumvent immunity previous infection or vaccination. article reviews number scientific considerations about these variants, including apparently reduced clinical severity.

Язык: Английский

Процитировано

80
Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2 DOI Creative Commons

Dinah V. Parums

Medical Science Monitor, Год журнала: 2023, Номер 29

Опубликована: Авг. 22, 2023

A new variant of SARS-CoV-2 has currently achieved global domination.EG.5 (Eris) was first reported by the World Health Organization (WHO) on February 17, 2023, and designated as a under monitoring (VUM) July 19, 2023.EG.5 (Eris), its sublineages, EG.5.1, EG.5.1.1,and EG.5.2, is descendent lineage XBB.1.9.2, which same spike amino acid profile XBB.1.5(Kraken).However, EG.5 an additional F456L mutation in protein compared to these parent subvariants, subvariant EG.5.1 another mutation, Q52H.Following risk evaluation WHO, sublineages were interest (VOI) August 8, 2023.In US, Centers for Disease Control Prevention (CDC) provides two-weekly data incidence mortality from COVID-19 variants.The most recent CDC showed increase cases past two weeks, with hospitalizations increasing 14.3% rising 8.3%.In common have been due three Omicron variants: (20.6%);FL.1.5.1 (Fornax) (13.3%); XBB.1.16(Arcturus) (10.7%).This Editorial aims highlight importance rapid virus genomic sequencing continued surveillance identify rapidly emerging variants, such (Eris).

Язык: Английский

Процитировано

45
Recent developments in the immunopathology of COVID‐19 DOI Creative Commons
Huanping Zhang,

Yuanli Sun,

Yanfen Wang

и другие.

Allergy, Год журнала: 2022, Номер 78(2), С. 369 - 388

Опубликована: Ноя. 24, 2022

Abstract There has been an important change in the clinical characteristics and immune profile of Coronavirus disease 2019 (COVID‐19) patients during pandemic thanks to extensive vaccination programs. Here, we highlight recent studies on COVID‐19, from immunological protective risk factors for severity mortality COVID‐19. The efficacy COVID‐19 vaccines potential allergic reactions after administration are also discussed. occurrence new variants concerns such as Omicron BA.2, BA.4, BA.5 global have changed scenario Multisystem inflammatory syndrome children (MIS‐C) may cause severe heterogeneous but with a lower rate. Perturbations immunity T cells, B mast well autoantibodies metabolic reprogramming contribute long‐term symptoms is conflicting evidence about whether atopic diseases, asthma rhinitis, associated susceptibility better outcomes At beginning pandemic, European Academy Allergy Clinical Immunology (EAACI) developed guidelines that provided timely information management diseases preventive measures reduce transmission clinics. distribution emerging acute respiratory coronavirus 2 (SARS‐CoV‐2) reduced pathogenic dramatically decreased morbidity, severity, Nevertheless, breakthrough infection remains challenge control. Hypersensitivity (HSR) low compared other vaccines, these were addressed EAACI statements indications reactions, including anaphylaxis vaccines. We gained depth knowledge experience over years since start yet full eradication SARS‐CoV‐2 not horizon. Novel strategies warranted prevent high‐risk groups, development MIS‐C long

Язык: Английский

Процитировано

68
Next-generation nanophotonic-enabled biosensors for intelligent diagnosis of SARS-CoV-2 variants DOI Open Access
Bakr Ahmed Taha, Yousif Al Mashhadany, Qussay Al-Jubouri

и другие.

The Science of The Total Environment, Год журнала: 2023, Номер 880, С. 163333 - 163333

Опубликована: Апрель 6, 2023

Язык: Английский

Процитировано

39
Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges DOI Creative Commons
Thirumalaisamy P. Velavan, Francine Ntoumi, Peter G. Kremsner

и другие.

International Journal of Infectious Diseases, Год журнала: 2023, Номер 128, С. 307 - 309

Опубликована: Янв. 19, 2023

Язык: Английский

Процитировано

37
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines DOI
Congrui Zhu,

Shengmei Pang,

Jiaqi Liu

и другие.

Drugs, Год журнала: 2024, Номер 84(4), С. 403 - 423

Опубликована: Апрель 1, 2024

Язык: Английский

Процитировано

10
Zoonosis and zooanthroponosis of emerging respiratory viruses DOI Creative Commons
Ahmed Magdy Khalil, Luis Martínez‐Sobrido,

Ahmed Mostafa

и другие.

Frontiers in Cellular and Infection Microbiology, Год журнала: 2024, Номер 13

Опубликована: Янв. 5, 2024

Lung infections in Influenza-Like Illness (ILI) are triggered by a variety of respiratory viruses. All human pandemics have been caused the members two major virus families, namely Orthomyxoviridae (influenza A viruses (IAVs); subtypes H1N1, H2N2, and H3N2) Coronaviridae (severe acute syndrome coronavirus 2, SARS−CoV−2). These acquired some adaptive changes known intermediate host including domestic birds (IAVs) or unknown (SARS-CoV-2) following transmission from their natural reservoirs (e.g. migratory bats, respectively). Verily, these substitutions facilitated crossing species barriers to infect humans phenomenon that is as zoonosis. Besides, aided variant strain transmit horizontally other contact non-human animal pets wild animals (zooanthroponosis). Herein we discuss main zoonotic reverse-zoonosis events occurred during last influenza A/H1N1 SARS-CoV-2. We also highlight impact interspecies pandemic on evolution possible prophylactic therapeutic interventions. Based information available presented this review article, it important close monitoring viral zoonosis reverse strains within One-Health One-World approach mitigate unforeseen risks, such resistance limited

Язык: Английский

Процитировано

9
A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2 DOI Creative Commons

Shanhong Mao,

Shiyou Li, Yuxin Zhang

и другие.

Nano Today, Год журнала: 2022, Номер 48, С. 101730 - 101730

Опубликована: Дек. 21, 2022

Despite the various vaccines that have been developed to combat coronavirus disease 2019 (COVID-19) pandemic, persistent and unpredictable mutations of severe acute respiratory syndrome 2 (SARS-CoV-2) require innovative unremitting solutions cope with resultant immune evasion establish a sustainable barrier. Here we introduce vaccine-delivery system combination needle-free injection (NFI) device SARS-CoV-2-Spike-specific mRNA-Lipid Nanoparticle (LNP) vaccine. The benefits are duller pain significant increase immunogenicity compared canonical needle (NI). From physicochemical bioactivity analyses, structure mRNA-LNP maintains stability upon NFI, contradictory belief LNPs inclined towards destruction under high-pressure conditions NFI. Moreover, vaccine delivered by NFI induces significantly more binding neutralizing antibodies against SARS-CoV-2 variants than same NI. Heterogeneous vaccination BA.5-LNP enhanced generation Omicron BA.5 in rabbits previously vaccinated non-BA.5-specific or other COVID-19 vaccines. parameters can be adjusted deliver subcutaneously intramuscularly. Taken together, our results suggest NFI-based is an effective substitute for traditional NI-based vaccination.

Язык: Английский

Процитировано

28
Computational screening combined with well-tempered metadynamics simulations identifies potential TMPRSS2 inhibitors DOI Creative Commons

C. S. Sharanya,

D. Sasikala Wilbee,

Shijulal Nelson‐Sathi

и другие.

Scientific Reports, Год журнала: 2024, Номер 14(1)

Опубликована: Июль 13, 2024

Abstract Type-II transmembrane serine proteases are effective pharmacological targets for host defence against viral entry and in certain cancer cell progressions. These cleave spike proteins to expose the fusion peptide entry, which is essential life cycle of virus. TMPRSS2 inhibitors can also fight respiratory viruses that employ them entry. Our study combining virtual screening, all-atom molecular dynamics, well-tempered metadynamics simulation identifies vicenin-2, neohesperidin, naringin, rhoifolin as promising antagonists. The binding energies obtained − 16.3, 15.4, 13.6, 13.8 kcal/mol respectively. RMSD, RMSF, PCA, DCCM, free energy profiles correlate with stable these ligands at active site TMPRSS2. reveals molecules could be lead combating future outbreaks coronavirus other viruses.

Язык: Английский

Процитировано

7
SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies DOI Creative Commons
Hailong Guo, Sha Ha, Jason Botten

и другие.

Viruses, Год журнала: 2024, Номер 16(5), С. 697 - 697

Опубликована: Апрель 28, 2024

Since the SARS-CoV-2 Omicron virus has gained dominance worldwide, its continual evolution with unpredictable mutations and patterns revoked all authorized immunotherapeutics. Rapid viral also necessitated several rounds of vaccine updates in order to provide adequate immune protection. It remains imperative understand how evolves into different subvariants causes escape as this could help reevaluate current intervention strategies mostly implemented clinics emergency measures counter pandemic and, importantly, develop new solutions. Here, we a review focusing on major events evolution, including features spike mutation that lead evasion against monoclonal antibody (mAb) therapy vaccination, suggest alternative durable options such ACE2-based experimental therapies superior mAbs address unprecedented virus. In addition, type unique virus-trapping molecules can zoonotic SARS coronaviruses, either from unknown animal hosts or established wild-life reservoirs SARS-CoV-2, even seasonal alpha coronavirus NL63 depends human ACE2 for infection.

Язык: Английский

Процитировано

6